美国药师合作实践协议(CPA)介绍及对我国的启示  

Introduction to CPA and its implications for China

作　　者：刘秋风 田侃[2] 喻小勇[2] LIU Qiu-feng;TIAN Kan;YU Xiao-yong(Jiangsu College of Nursing,Jiangsu Huaian 223001,China;Nanjing University of Traditional Chinese Medicine,Jiangsu Nanjing 210000,China)

机构地区：[1]江苏护理职业学院,江苏淮安223001 [2]南京中医药大学,江苏南京210000

出　　处：《中国医院药学杂志》2020年第10期1170-1173,共4页Chinese Journal of Hospital Pharmacy

基　　金：国家卫生计生委政策研究项目“基层医疗卫生机构合理用药服务包政策研究”(药政2016[56])。

摘　　要：目的:本文在查阅分析国外文献的基础上介绍了美国药师合作实践协议(CPA)的形成背景、发展历程、立法情况、核心要素,以期为我国实行CPA与药师角色转型提供启示。借鉴美国药师合作实践协议(CPA)发展的经验,同时基于中国的实际情况,对我国实行CPA,从扩大我国药师实践范围、建立药师与医师之间的信任、提高我国药师专业能力、明确合作协议中药师的责任以及制定药师服务费用标准5个方面提供可行性建议。Based on the review and analysis of foreign literatures,this paper introduces the formation background,development history,legislation and core elements of American Pharmacist Cooperation Practice Agreement(CPA),in order to provide inspiration for the implementation of CPA and pharmacist role transformation in China.With great reference the experience of the development of the Collaborative Practice Agreement(CPA)for Pharmacists in the United States,and the actual situation in China,CPA is implemented in China to provide feasibility suggestions from five aspects:expanding the scope of pharmacist practice in China,establishing trust between pharmacists and physicians,improving the professional ability of pharmacists in China,clarifying the responsibilities of pharmacists in the cooperation agreement,and formulating pharmacist service cost standards.

关 键 词：药师合作实践协议 合作药物治疗管理 药师 美国 

分 类 号：R954[医药卫生—药学]